According to Future Market Insights, the global allogeneic T cell therapies market was anticipated to reach a valuation of USD 1.1 billion in the year 2022. Expected to register a CAGR of 9.8% from 2023 to 2033, this market is expected to reach USD 1.21 billion by 2023, and eventually to USD 3.08 billion by 2033.
The market for allogeneic T-cell therapy is primarily driven by rising investments in the development of innovative gene therapy-based chemotherapy drugs, rising market accessibility of cell therapy, rising expenditure in T-cell therapies, and technical breakthroughs in diagnostic technologies.
In allogeneic T-cell therapy, healthy people's cells are given to patients to treat a variety of chronic illnesses, including cancer and cardiovascular conditions. The harvested donor cells may be given directly to a patient who shares their genetic makeup or added to a cell bank. Bulk batches of allogenic T-cell treatments are produced using different donor tissues, such as bone marrow. The processes utilized in the scale-up manufacture are comparable to those in the production of protein medicines and other large-scale derived materials. These treatments offer a number of benefits, including being easier to automate, more affordable than autologous therapies, and available as a scalable off-the-shelf product. Thus, these benefits are expected to enhance the global demand for the allogeneic T-cell therapy market from 2023 to 2033.
Increased T-cell research activities and an increase in permissions for GMP-certified institutions to perform cell research and treatments are two factors driving the growth of the allogeneic T-cell therapy market. The demand for novel and improved therapies for neurodegenerative, immunological, as well as myocardial infarctions has resulted in increasing research effort, financing, and desire for allogeneic T-cell therapy.
The key factors influencing the worldwide market for allogeneic T-cell treatment are rising unmet demands for the treatment of long-term illnesses and increased financing for T-cell research. A number of tissue-engineered treatments as well as allogeneic and autologous cell treatments are now being developed by several pharmaceutical companies.
The market for allogeneic T-cell treatment is projected to expand due to the increasing demand for gene and cell therapy as well as the use of induced pluripotent cells instead of embryonic stem cells. The prevalence of cancer as one of the leading killers worldwide has increased public awareness of the disease and the most innovative cell therapies available today.
Also, it is anticipated that the FDA would approve more allogeneic T-cell treatments to treat autoimmune and cardiac illnesses. For instance, in December 2022, the FDA approved BioCardia, Inc.'s IND application to begin a human clinical study using allogeneic human MSC that are Neurokinin-1 receptor positive (NK1R+) to treat patients with ischemic heart failure. The FDA also approved Talaris Therapeutics, Inc.'s IND application for its innovative allogeneic T-cell treatment FCR001 for systemic sclerosis patients in July 2020.
To create innovative allogeneic cell treatments, the major market participants are putting many strategic efforts into practice. For instance, Bristol Myers Squibb and Century Therapeutics entered into a strategic partnership in January 2022 to develop allogeneic medicines produced from iPSCs for solid tumors and hematologic malignancies. Thus, the market for allogeneic T-cell treatment is anticipated to grow throughout the forecast years due to an increase in FDA approvals and strategic moves by key industry participants.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value of Allogenic T-Cell Therapies in 2023 | USD 1.21 billion |
| Expected Market Value of Allogenic T-Cell Therapies in 2033 | USD 3.08 billion |
| Growth Rate (2023 to 2033) | CAGR of 9.8% |
Allogeneic T cell therapies depend on a single source of cells for the treatment of various patients. In this, the cells are collected from the donor for the creation of the master cell bank. The Master cell bank is utilized as the source for the creation of cell populace that is further processed as per the demands of the specific treatment.
While the final cell populace is then utilized for the treatment of multiple patients. The allogeneic T cell therapies have various advantages such as the immediate readiness of the cryopreserved batches for the patient therapy, standardization of the CAR-T cell, time for cell modifications, the collaboration of CAR T cells directed against the varied targets, redosing and lower costs using an industrialized procedure.
CAR-T and TCR-T therapies have already revolutionized blood cancer treatment. Researchers Duke-NUS Medical School are examining the capability of turning this approach for the treatment of coronavirus patients.
Scientists also informed that these immunotherapies might also beneficial in the treatment of SARS-CoV-2, the virus resulting in the current outbreak. Various companies are working on cell therapies for coronavirus. AlloVir & Baylor College of Medicine are collaborated to produce an innovative therapy to treat the coronavirus.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing cases of cancer and a rising variety of patients with failure response to varied treatments are witnessed to boosts the allogeneic T cell therapy market growth globally. Additionally, increasing prevalence of cancer in geriatric & pediatric patients is projected to results in higher demand for an efficient and reliable treatment approach for the improvement of quality of patient’s lives.
Moreover, rising government activities for improving healthcare insurance framework and advancement in research & development activities for allogeneic T cell therapy is fueling the development of the allogeneic T cell therapy market.
Meanwhile, side effects related to the allogeneic T cell therapy may result in cytokine release syndrome & other neurological disorders including coma, seizures, delirium and hallucinations. This factor is witnessed to restrain the allogeneic T cell therapy market growth.
CD19 target antigens are witnessed to hold the dominant market share owing to the reality that end number of the companies were capable to receive their antigens approved & hence, commercialized them.
Additionally, the diagnostic centers segment held the largest share owing to the rising research and development activities and the utilization of engineered cell therapy in molecular diagnostics. However, the acute lymphoblastic leukaemia has a dominant market share as allogeneic T Cell Therapy offers a therapeutic advantage for the patients who are suffering from the failure of conventional therapy.
Principal Consultant
Geographically, the allogeneic T cell therapies market is segregated into seven regions viz. Asia Pacific, North America & Latin America, Eastern Europe Western Europe, Japan, & the Middle East and Africa.
North America is expected to dominate the global allogeneic T cell therapies market followed by Europe & Asia Pacific. North America is expected to dominate the global allogeneic T cell therapies market due to the rising venture and research & development activities for the improvement of malignancy treatments in this region.
Meanwhile, Asia Pacific is witnessed to show remarkable developments over the gauge time frame owing to the expanding number of worldwide players teaming up just as assembling contracts for allogeneic T cell treatments with local players in the region.
The key participants operating in the global Allogeneic T cell therapies market identified across the value chain include
The major players are concentrating on the vital merger and securing to upgrade their share in the worldwide allogeneic T cell treatment market. For example, in April 2018, Pfizer, Inc. marked an arrangement with Allogene, to build up an investigational CAR-T cell treatment for rewarding malignant growth.
In January 2019, Novartis declared that they will procure CellforCure with the goal that they can grow their cell and quality treatment. This securing will assist the organization with making their Allogeneic T cell therapies Therapy Kymriah accessible for a huge number of patients worldwide and will likewise assist them with improving their assembling limit of cell and quality treatments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global allogeneic T cell therapies market has been segregated based on antigen type, indication, end-user and geography.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Antigen Type 6.2. Indication 6.3. End-User 7. Global Market Analysis and Forecast, By Antigen Type 7.1. CD 19 7.2. CD 20 7.3. Egfrvlll 7.4. GD2 7.5. CD22 7.6. CD30 7.7. CD33 7.8. Meso 7.9. HER1 7.10. HER2 7.11. Egfrvlll 8. Global Market Analysis and Forecast, By Indication 8.1. Diffuse Large B-Cell Lymphoma 8.2. Multiple Myeloma 8.3. Acute Lymphoblastic Leukemia 8.4. Chronic Lymphocytic Leukemia 8.5. Follicular Lymphoma 8.6. Others 9. Global Market Analysis and Forecast, By End-User 9.1. Research Institutes 9.2. Biotechnological & pharmaceutical organizations 9.3. Diagnostic centers or labs 9.4. Academics or educational centers 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Asia Pacific 10.5. Japan 10.6. The Middle East and Africa 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. Japan Sales Analysis and Forecast, by Key Segments and Countries 16. The Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Antigen Type, Indication, and End-User for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Autolus 19.2. TrakCel 19.3. Tmunity Therapeutics 19.4. Bellicum Pharmaceuticals Inc. 19.5. Sorrento Therapeutics 19.6. Bluebird Inc. 19.7. Minerva Biotechnologies Corporation 19.8. Kite Pharma 19.9. CELGENE CORPORATION 19.10. Cellectis 19.11. Fortress Biotech 19.12. Promab Biotechnologies 19.13. Immune Therapeutics 19.14. Ziopharm Oncology Inc 19.15. Juno Therapeutics 19.16. Novartis AG 19.17. Celyad 19.18. Eureka Therapeutics Inc. 19.19. TILT Biotherapeutics 19.20. Poseida Therapeutics Inc.
Healthcare
April 2023
REP-GB-16106
303 pages
Explore Healthcare Insights
View Reports
Allogeneic T Cell Therapies Market
